company background image
BIOG

BioGaiaOM:BIOG B Stock Report

Last Price

kr490.50

Market Cap

kr9.9b

7D

-3.3%

1Y

-3.1%

Updated

23 Jan, 2022

Data

Company Financials +
BIOG B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance3/6
Financial Health6/6
Dividends3/6

BIOG B Stock Overview

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide.

Rewards

Earnings are forecast to grow 9.35% per year

Earnings have grown 3.1% per year over the past 5 years

Risk Analysis

No risks detected for BIOG B from our risk checks.

BioGaia Competitors

Novartis

SWX:NOVN

CHF178.7b

Price History & Performance

Summary of all time highs, changes and price drops for BioGaia
Historical stock prices
Current Share Pricekr490.50
52 Week Highkr584.00
52 Week Lowkr394.50
Beta0.79
1 Month Change-3.06%
3 Month Change-3.82%
1 Year Change-3.06%
3 Year Change32.75%
5 Year Change53.52%
Change since IPO1,141.78%

Recent News & Updates

Shareholder Returns

BIOG BSE BiotechsSE Market
7D-3.3%-2.6%-2.8%
1Y-3.1%-5.5%15.9%

Return vs Industry: BIOG B exceeded the Swedish Biotechs industry which returned -5.5% over the past year.

Return vs Market: BIOG B underperformed the Swedish Market which returned 15.9% over the past year.

Price Volatility

Is BIOG B's price volatile compared to industry and market?
BIOG B volatility
BIOG B Average Weekly Movement5.0%
Biotechs Industry Average Movement8.2%
Market Average Movement6.7%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market3.9%

Stable Share Price: BIOG B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BIOG B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990159Isabelle Valerie Ducellierhttps://www.biogaia.com

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.

BioGaia Fundamentals Summary

How do BioGaia's earnings and revenue compare to its market cap?
BIOG B fundamental statistics
Market Capkr9.91b
Earnings (TTM)kr196.47m
Revenue (TTM)kr766.56m

50.4x

P/E Ratio

12.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOG B income statement (TTM)
Revenuekr766.56m
Cost of Revenuekr202.68m
Gross Profitkr563.88m
Expenseskr367.41m
Earningskr196.47m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 04, 2022

Earnings per share (EPS)9.73
Gross Margin73.56%
Net Profit Margin25.63%
Debt/Equity Ratio0%

How did BIOG B perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

35%

Payout Ratio

Valuation

Is BioGaia undervalued compared to its fair value and its price relative to the market?

50.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIOG B (SEK490.5) is trading above our estimate of fair value (SEK348.94)

Significantly Below Fair Value: BIOG B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIOG B's PE Ratio (50.4x) is in line with the Swedish Biotechs industry average.

PE vs Market: BIOG B is poor value based on its PE Ratio (50.4x) compared to the Swedish market (22.2x).


Price to Earnings Growth Ratio

PEG Ratio: BIOG B is poor value based on its PEG Ratio (5.4x)


Price to Book Ratio

PB vs Industry: BIOG B is overvalued based on its PB Ratio (5.4x) compared to the SE Biotechs industry average (3.1x).


Future Growth

How is BioGaia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

9.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOG B's forecast earnings growth (9.4% per year) is above the savings rate (0.3%).

Earnings vs Market: BIOG B's earnings (9.4% per year) are forecast to grow faster than the Swedish market (0.7% per year).

High Growth Earnings: BIOG B's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIOG B's revenue (12% per year) is forecast to grow faster than the Swedish market (1.6% per year).

High Growth Revenue: BIOG B's revenue (12% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIOG B's Return on Equity is forecast to be low in 3 years time (11.4%).


Past Performance

How has BioGaia performed over the past 5 years?

3.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIOG B has high quality earnings.

Growing Profit Margin: BIOG B's current net profit margins (25.6%) are higher than last year (25.3%).


Past Earnings Growth Analysis

Earnings Trend: BIOG B's earnings have grown by 3.1% per year over the past 5 years.

Accelerating Growth: BIOG B's earnings growth over the past year (1.4%) is below its 5-year average (3.1% per year).

Earnings vs Industry: BIOG B earnings growth over the past year (1.4%) underperformed the Biotechs industry 1.4%.


Return on Equity

High ROE: BIOG B's Return on Equity (10.7%) is considered low.


Financial Health

How is BioGaia's financial position?


Financial Position Analysis

Short Term Liabilities: BIOG B's short term assets (SEK1.7B) exceed its short term liabilities (SEK104.1M).

Long Term Liabilities: BIOG B's short term assets (SEK1.7B) exceed its long term liabilities (SEK24.8M).


Debt to Equity History and Analysis

Debt Level: BIOG B is debt free.

Reducing Debt: BIOG B has not had any debt for past 5 years.

Debt Coverage: BIOG B has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BIOG B has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is BioGaia current dividend yield, its reliability and sustainability?

0.69%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BIOG B's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.04%).

High Dividend: BIOG B's dividend (0.7%) is low compared to the top 25% of dividend payers in the Swedish market (3.42%).


Stability and Growth of Payments

Stable Dividend: BIOG B's dividend payments have been volatile in the past 10 years.

Growing Dividend: BIOG B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (34.5%), BIOG B's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BIOG B's dividends in 3 years are forecast to be well covered by earnings (44.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Isabelle Valerie Ducellier (52 yo)

no data

Tenure

kr3,217,000

Compensation

Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer and President of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. She serves as a Board Membe...


CEO Compensation Analysis

Compensation vs Market: Isabelle Valerie's total compensation ($USD350.47K) is below average for companies of similar size in the Swedish market ($USD627.67K).

Compensation vs Earnings: Isabelle Valerie's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BIOG B's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: BIOG B's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioGaia AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: BioGaia AB (publ)
  • Ticker: BIOG B
  • Exchange: OM
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr9.906b
  • Shares outstanding: 20.20m
  • Website: https://www.biogaia.com

Number of Employees


Location

  • BioGaia AB (publ)
  • Kungsbroplan 3
  • Stockholm
  • Stockholm County
  • 112 27
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 18:45
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.